Literature DB >> 14521421

Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance.

Siska Cochran1, Caiping Li, Jon K Fairweather, Warren C Kett, Deirdre R Coombe, Vito Ferro.   

Abstract

The binding interactions of the phosphosulfomannan anticancer agent PI-88 (1) with the angiogenic growth factors FGF-1, FGF-2, and VEGF were studied by surface plasmon resonance (SPR) on a BIAcore 3000 biosensor. Compared with heparin, PI-88 has at least 11-fold higher affinity for FGF-1 and at least 3-fold higher affinity for VEGF, but at least 13-fold lower affinity for FGF-2. To define the structural features of PI-88 that are important for growth factor binding, several analogues, such as dephosphorylated PI-88 and a sulfated pentasaccharide, were prepared. The binding interactions of these analogues with FGF-1, FGF-2, and VEGF were similarly studied by SPR, and structure-activity relationships were determined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521421     DOI: 10.1021/jm030180y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Validation of arrayed imaging reflectometry biosensor response for protein-antibody interactions: cross-correlation of theory, experiment, and complementary techniques.

Authors:  Rashmi Sriram; Amrita R Yadav; Charles R Mace; Benjamin L Miller
Journal:  Anal Chem       Date:  2011-04-25       Impact factor: 6.986

2.  Structural insights into proteoglycan-shaped Hedgehog signaling.

Authors:  Daniel M Whalen; Tomas Malinauskas; Robert J C Gilbert; Christian Siebold
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

3.  A novel FGF2 antagonist peptide P8 with potent antiproliferation activity.

Authors:  Lei Fan; Hang Xie; Lingzi Chen; Hui Ye; Shilong Ying; Cong Wang; Xiaoping Wu; Wulan Li; Jianzhang Wu; Guang Liang; Xiaokun Li
Journal:  Tumour Biol       Date:  2014-07-26

Review 4.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

Review 5.  Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Authors:  Israel Vlodavsky; Miry Blich; Jin-Ping Li; Ralph D Sanderson; Neta Ilan
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

6.  The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.

Authors:  K Dredge; E Hammond; K Davis; C P Li; L Liu; K Johnstone; P Handley; N Wimmer; T J Gonda; A Gautam; V Ferro; I Bytheway
Journal:  Invest New Drugs       Date:  2009-04-09       Impact factor: 3.850

7.  A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.

Authors:  Karl D Lewis; William A Robinson; Michael J Millward; Alex Powell; Timothy J Price; Damien B Thomson; Euan T Walpole; Andrew M Haydon; Brian R Creese; Kaye L Roberts; John R Zalcberg; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2007-09-20       Impact factor: 3.850

Review 8.  The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

Authors:  Vishnu C Ramani; Anurag Purushothaman; Mark D Stewart; Camilla A Thompson; Israel Vlodavsky; Jessie L-S Au; Ralph D Sanderson
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

9.  Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.

Authors:  Chun-Jen Liu; Juliana Chang; Po-Huang Lee; Deng-Yn Lin; Cheng-Chung Wu; Long-Bin Jeng; Yih-Jyh Lin; King-Tong Mok; Wei-Chen Lee; Hong-Zen Yeh; Ming-Chih Ho; Sheng-Shun Yang; Mei-Due Yang; Ming-Chin Yu; Rey-Heng Hu; Cheng-Yuan Peng; Kuan-Lang Lai; Stanley Shi-Chung Chang; Pei-Jer Chen
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

10.  Profiling heparin-chemokine interactions using synthetic tools.

Authors:  Jose L de Paz; E Ashley Moseman; Christian Noti; Laura Polito; Ulrich H von Andrian; Peter H Seeberger
Journal:  ACS Chem Biol       Date:  2007-11-20       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.